Previous studies in animal models of kidney diseases have shown that ASK1 promotes p38 MAPK activation induced by oxidative stress, whereas ASK1 deficiency or ASK1-selective inhibition reduces p38 MAPK and JNK activation and improves kidney injury in mouse models of CKD and fibrosis 193-195. Here, MAP3K5 is linked to chronic kidney disease.